Dashboard
Weak Long Term Fundamental Strength with a 41.32% CAGR growth in Operating Profits over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.47
- The company has been able to generate a Return on Equity (avg) of 2.79% signifying low profitability per unit of shareholders funds
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Healthcare Services
INR 28 Cr (Micro Cap)
7.00
43
0.00%
-0.02
7.43%
0.54
Total Returns (Price + Dividend) 
Latest dividend: 1.2000 per share ex-dividend date: Sep-21-2010
Risk Adjusted Returns v/s 
Returns Beta
News

GKB Ophthalmics Downgraded to Sell Amid Mixed Financial and Technical Signals
GKB Ophthalmics Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a complex interplay of deteriorating technical indicators, cautious valuation metrics, and mixed financial trends. Despite recent positive earnings growth, concerns over long-term fundamentals and technical signals have prompted a reassessment of the stock’s outlook.
Read More
GKB Ophthalmics Upgraded to Hold on Improved Technicals and Financial Performance
GKB Ophthalmics Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and financial performance. The company’s recent quarterly results, combined with a bullish shift in technical trends, have prompted analysts to revise their outlook, signalling cautious optimism for this healthcare services micro-cap.
Read More
GKB Ophthalmics Downgraded to Sell Amid Mixed Financials and Weak Technicals
GKB Ophthalmics Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a combination of deteriorating technical indicators, weak long-term fundamentals, and mixed financial trends. Despite recent positive quarterly results, the company’s overall outlook has been tempered by underperformance against benchmarks and a shift in technical momentum.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
14-Nov-2026 | Source : BSEPlease find attached copies of newspaper cuttings of the extract of Statement of unaudited Standalone and Consolidated financial Results for the quarter and half year ended September 302026 published in Business Standard ( English Edition) and on Pudhari (Marathi) dated November 14 2026.
Financial Results Of The Company For The Quarter And Half Year Ended September 30 2026.
12-Nov-2026 | Source : BSEEnclosed please find the unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30 2026.
Board Meeting Outcome for Outcome Of The Board Meeting Held On November 12 2026.
12-Nov-2026 | Source : BSEThe meeting of the Board of Directors of the company was held on November 12 2026 which has inter-alia considered and took on record the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2026.
Corporate Actions 
No Upcoming Board Meetings
GKB Ophthalmics Ltd has declared 12% dividend, ex-date: 21 Sep 10
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 1 FIIs (1.79%)
Krishna Gopal Gupta (17.91%)
Krishna Murari Gupta (5.54%)
39.87%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is -0.88% vs 10.91% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is -34.65% vs 431.58% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 19.79% vs 22.27% in Sep 2024
Growth in half year ended Sep 2025 is 139.46% vs -129.69% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 52.99% vs 16.88% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 129.14% vs -85.19% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 36.76% vs 23.50% in Mar 2025
YoY Growth in year ended Mar 2026 is 117.33% vs -150.53% in Mar 2025